Literature DB >> 9136824

Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.

G D'Haens1, K Geboes, E Ponette, F Penninckx, P Rutgeerts.   

Abstract

BACKGROUND & AIMS: Standard corticosteroid therapy for Crohn's ileitis induces symptom relief without improvement of endoscopically visible lesions. In this study, the effect of azathioprine therapy on the inflammatory lesions in the neoterminal ileum of patients with severe postoperative Crohn's recurrence was examined.
METHODS: Macroscopic ileal lesions were studied endoscopically or radiologically after at least 6 months of azathioprine therapy after complete weaning of corticosteroids. All patients who underwent an ileocecal resection for Crohn's disease at our institution between January 1989 and December 1993 and who subsequently developed severe recurrent ileitis treated with azathioprine were included.
RESULTS: Of the 19 patients treated with azathioprine for recurrent ileitis, 15 could be reevaluated by endoscopy or radiological examination. The therapy resulted in induction and maintenance of clinical remission in all 15 patients, at least 6 months after complete weaning of the corticosteroids. Complete macroscopic healing of the neoterminal ileum was observed in 6 of 15 patients, near-complete healing with only superficial erosions remaining in 5 of 15 patients, partial healing in 3 of 15 patients, and unchanged inflammatory lesions in 1 patient.
CONCLUSIONS: It is concluded that azathioprine leads to mucosal healing in severe recurrent Crohn's ileitis and may be the treatment of choice in this indication.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9136824     DOI: 10.1016/s0016-5085(97)70027-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  58 in total

1.  New treatments for inflammatory bowel disease.

Authors:  David S Rampton; D Phil
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Management of difficult inflammatory bowel disease: where are we now?

Authors:  DS Rampton
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

Review 3.  Prevention of postoperative recurrence in Crohn's disease.

Authors:  G D'Haens
Journal:  Curr Gastroenterol Rep       Date:  1999-12

4.  Serial intralesional injections of infliximab in small bowel Crohn's strictures are feasible and might lower inflammation.

Authors:  Jakob Hendel; John Gásdal Karstensen; Peter Vilmann
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

5.  Ileal Crohn's disease is best treated by surgery.

Authors:  M J G Farthing
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 6.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 7.  Role of endoscopy in predicting the disease course in inflammatory bowel disease.

Authors:  Matthieu Allez; Marc Lémann
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

8.  Immunomodulators for all patients with inflammatory bowel disease?

Authors:  Sandro Ardizzone; Andrea Cassinotti; Gianpiero Manes; Gabriele Bianchi Porro
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

9.  Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001.

Authors:  H Hildebrand; Y Finkel; L Grahnquist; J Lindholm; A Ekbom; J Askling
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 10.  Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease.

Authors:  María Josefina Etchevers; Montserrat Aceituno; Miquel Sans
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.